BioCentury
ARTICLE | Company News

iBio, Medical University of South Carolina, University of Pittsburgh deal

February 10, 2014 8:00 AM UTC

The University of Pittsburgh granted iBio an exclusive license to patents and IP for an endostatin-derived peptide for idiopathic pulmonary fibrosis (IPF) and systemic sclerosis. iBio then partnered with Medical University of South Carolina (MUSC) to test the peptide made by iBio using its iBioLaunch technology in MUSC's preclinical models. The iBioLaunch technology uses transient gene expression in unmodified green plants. iBio plans to begin clinical testing of the peptide this year and said it will request breakthrough therapy designation from FDA if clinical data are consistent with preclinical results. iBio declined to disclose financial details. ...